跳至主要内容
临床试验/NCT01401673
NCT01401673终止2 期

Phase II Open-label Pilot Study of V3381, a Novel N-Methyl-D-Aspartate Receptor Antagonist, in Chronic Cough Patients Attending a Specialist Clinic

Vernalis (R&D) Ltd2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2009年10月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
终止
入组人数
12
试验地点
2
主要终点
Objective cough frequency at 8 weeks compared to baseline.

研究概览

简要总结

The investigators hypothesise that cough reflex hypersensitivity, demonstrated in chronic cough patients, is due to a phenomenon known as central sensitisation. Central sensitisation is a hyper-excitability of the sensory nerves as they join the central nervous system, and is believed to be mediated by the N-Methyl-D-Aspartate (NMDA) receptor[1-3].

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female 18-75 years of age
  • Females must be of non child-bearing potential
  • Chronic Cough ( > 8 weeks)
  • Normal Chest X-ray
  • Normal Lung Function
  • Idiopathic or treatment resistant cough-

排除标准

  • Recent upper respiratory tract infection (<4 weeks)
  • Pregnancy/breast-feeding
  • Current smokers or ex-smokers with <6 months abstinence or cumulative history of >10 pack years
  • Current treatment with ACE inhibitors.
  • Drug or alcohol abuse
  • Uncontrolled hypertension (i.e., >140/90 mmHg despite adequate medical therapy).
  • Any cardiovascular condition that would be a contra-indication to the use of sympathomimetic amines (e.g. active angina).
  • Any clinically significant neurological disorder
  • Prior renal transplant, current renal dialysis.
  • Any clinically significant or unstable medical or psychiatric condition that would interfere with the patient's ability to participate in the study.
  • Increased risk of seizures.
  • Any malignancy in the past 2 years (with the exception of basal cell carcinoma).
  • Use of opioids, anticonvulsants, antidepressants (particularly MAO inhibitors).
  • Any clinically significant abnormal laboratory test result(s).
  • Serum creatinine laboratory value greater than 1.5 x upper limit of normal (ULN) reference range (after adjustment for age) or estimated creatinine clearance <60 mL/min.
  • Total bilirubin greater than upper limit of normal reference range (with the exception of Gilbert's Syndrome) and/or alanine transaminase (ALT) >1.5 times upper limit of normal reference ranges (after adjustment for age).

结局指标

主要结局

Objective cough frequency at 8 weeks compared to baseline.

时间窗: 8 Weeks

次要结局

  • Change in objective cough frequency at 4 weeks.(4 Weeks)
  • Change in Cough-Specific Quality-of-Life Questionnaire (CQLQ) at 4 and 8 weeks.(4 and 8 Weeks)
  • Change in Global Rating of Change Scale at 1 week, 2 weeks, 4 weeks and 8 weeks(1 Week, 2 Weeks, 4 Weeks and 8 Weeks)

研究者

申办方类型
Industry

研究点 (2)

Loading locations...

相似试验